Julie E Chang1, Lakeesha L Carmichael2, KyungMann Kim2, Christopher Peterson3, David T Yang4, Anne M Traynor5, Jae E Werndli6, Michael S Huie5, Thomas A McFarland5, Michael Volk7, Jules Blank7, Natalie S Callander5, Walter L Longo5, Brad S Kahl8. 1. Department of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI. Electronic address: jc2@medicine.wisc.edu. 2. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI. 3. Department of Hematology/Oncology, Aspirus Cancer Center, Wausau, WI. 4. Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI. 5. Department of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI. 6. Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI. 7. Department of Hematology/Oncology, Saint Vincent Regional Cancer Center, Green Bay, WI. 8. Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO.
Abstract
INTRODUCTION: VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. PATIENTS AND METHODS: Patients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m2 × 4 weekly doses) and MR (375 mg/m2 every 12 weeks × 20 doses). The primary endpoints were overall and complete response (CR), and the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Thirty patients were enrolled, with a median age of 61 years. There was an even distribution of patients < 60 years and ≥ 60 years. Mantle cell lymphoma international prognostic index medium- or high-risk disease was present in 60%. The overall response rate observed was 90% (77% CR/unconfirmed CR). After a median follow-up of 7.8 years, the 6-year PFS and OS were 53% and 70%, respectively. There was no difference in 6-year PFS or OS between the younger (age < 60 years) and older (age ≥ 60 years) subgroups. In a univariate analysis, lactate dehydrogenase, when analyzed for interaction with age, had a significant effect on PFS outcomes at 6 years. There were no pretreatment variables determined to have a significant effect on OS outcomes at 6 years. CONCLUSIONS: Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous, and durable remission can be achieved with intermediate intensity therapy. MR appears to contribute to these excellent outcomes.
INTRODUCTION: VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger patients with MCL. PATIENTS AND METHODS: Patients with previously untreated MCL received VcR-CVAD induction chemotherapy for 6 cycles (21-day cycles). Patients achieving at least a partial response received rituximab consolidation (375 mg/m2 × 4 weekly doses) and MR (375 mg/m2 every 12 weeks × 20 doses). The primary endpoints were overall and complete response (CR), and the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Thirty patients were enrolled, with a median age of 61 years. There was an even distribution of patients < 60 years and ≥ 60 years. Mantle cell lymphoma international prognostic index medium- or high-risk disease was present in 60%. The overall response rate observed was 90% (77% CR/unconfirmed CR). After a median follow-up of 7.8 years, the 6-year PFS and OS were 53% and 70%, respectively. There was no difference in 6-year PFS or OS between the younger (age < 60 years) and older (age ≥ 60 years) subgroups. In a univariate analysis, lactate dehydrogenase, when analyzed for interaction with age, had a significant effect on PFS outcomes at 6 years. There were no pretreatment variables determined to have a significant effect on OS outcomes at 6 years. CONCLUSIONS: Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous, and durable remission can be achieved with intermediate intensity therapy. MR appears to contribute to these excellent outcomes.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Christian H Geisler; Arne Kolstad; Anna Laurell; Mats Jerkeman; Riikka Räty; Niels S Andersen; Lone B Pedersen; Mikael Eriksson; Marie Nordström; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen Journal: Br J Haematol Date: 2012-05-29 Impact factor: 6.998
Authors: Vaishalee P Kenkre; Walter L Long; Jens C Eickhoff; Jules H Blank; Thomas A McFarland; Wayne Bottner; Hamied Rezazedeh; Jae E Werndli; Howard H Bailey; Brad S Kahl Journal: Leuk Lymphoma Date: 2011-09
Authors: H C Kluin-Nelemans; E Hoster; O Hermine; J Walewski; M Trneny; C H Geisler; S Stilgenbauer; C Thieblemont; U Vehling-Kaiser; J K Doorduijn; B Coiffier; R Forstpointner; H Tilly; L Kanz; P Feugier; M Szymczyk; M Hallek; S Kremers; G Lepeu; L Sanhes; J M Zijlstra; R Bouabdallah; P J Lugtenburg; M Macro; M Pfreundschuh; V Procházka; F Di Raimondo; V Ribrag; M Uppenkamp; M André; W Klapper; W Hiddemann; M Unterhalt; M H Dreyling Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245
Authors: Tadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco Cavalli Journal: N Engl J Med Date: 2015-03-05 Impact factor: 91.245
Authors: B S Kahl; W L Longo; J C Eickhoff; J Zehnder; C Jones; J Blank; T McFarland; W Bottner; H Rezazedeh; J Werndli; H H Bailey Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: Julie E Chang; Christopher Peterson; Sangbum Choi; Jens C Eickhoff; KyungMann Kim; David T Yang; Leslie A Gilbert; Eric S Rogers; Jae E Werndli; Michael S Huie; Thomas A McFarland; Michael Volk; Jules Blank; Natalie S Callander; Walter L Longo; Brad S Kahl Journal: Br J Haematol Date: 2011-08-16 Impact factor: 6.998
Authors: Orion M Howard; John G Gribben; Donna S Neuberg; Michael Grossbard; Christina Poor; Milos J Janicek; Margaret A Shipp Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Christian W Eskelund; Arne Kolstad; Mats Jerkeman; Riikka Räty; Anna Laurell; Sandra Eloranta; Karin E Smedby; Simon Husby; Lone B Pedersen; Niels S Andersen; Mikael Eriksson; Eva Kimby; Hans Bentzen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Christopher T Workman; Christian Garde; Erkki Elonen; Peter Brown; Kirsten Grønbaek; Christian H Geisler Journal: Br J Haematol Date: 2016-07-05 Impact factor: 6.998